Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Kowalczyk

Adolescent Medicine Westfield, NJ Medical Doctor

NPI 1972548931 CMS profile 135163

532 E Broad St, Westfield, NJ 07090

Open in the dashboard

General payments

$2,326

159 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Kowalczyk of Westfield, NJ is reported in the CMS Open Payments database as having received $2,326 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $455 25
2024 General $255 15
2023 General $257 18
2022 General $412 33
2021 General $481 34
2020 General $199 14
2019 General $267 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Kowalczyk
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Matthew Kowalczyk were reported at $455. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Matthew Kowalczyk Adolescent Medicine median Middle half National median
2019 $267 $95 $36–$198 $163
2020 $199 $50 $23–$111 $114
2021 $481 $67 $27–$179 $132
2022 $412 $79 $29–$189 $149
2023 $257 $100 $39–$194 $160
2024 $255 $93 $38–$195 $164
2025 $455 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $392 26 payments
  2. Merck Sharp & Dohme Corporation $366 26 payments
  3. Pfizer Inc. $265 22 payments
  4. Sanofi Pasteur Inc. $236 12 payments
  5. Cranial Technologies, Inc $214 16 payments
  6. Supernus Pharmaceuticals, Inc. $147 11 payments
  7. Genentech USA, Inc. $102 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $86 6 payments
  9. Corium, Inc. $83 6 payments
  10. Sobi, Inc $62 4 payments
  11. Other $373 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,326 159 payments
Products named General payments · program years 2019–2025
  1. BEXSERO $392 26 payments
  2. GARDASIL 9 $328 23 payments
  3. PEDIARIX $252 16 payments
  4. Doc Band $214 16 payments
  5. TRUMENBA $207 18 payments
  6. VAXELIS $195 14 payments
  7. VAXNEUVANCE $193 13 payments
  8. BEYFORTUS $189 9 payments
  9. PREVNAR 13 $179 16 payments
  10. QELBREE $133 10 payments
  11. Other $1,635 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record